Clinical trial NCT06607757: Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Official title: Phase II Neoadjuvant Study Evaluating Capivasertib Plus Fulvestrant vs Fulvestrant in Patients With Primary High-risk Lobular Breast Cancer- LOBSTER
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Lead sponsor: GBG Forschungs GmbH
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2024-09-23
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Evaluation of treatment outcome
Primary purpose: TREATMENT

Brief summary: This is a multicenter, prospective, open-label, randomized phase II study to evaluate the CCCA assessed by Ki67 drop below \&lt;2.7% from baseline to week 2 (window of opportunity) and to week 10 with capivasertib plus fulvestrant compared with fulvestrant alone as neoadjuvant treatment for primary high-risk lobular breast cancer patients.

120 patients will be randomized to receive:

- Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)

or

- Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations) Treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient.

All patients will undergo core-biopsies, under treatment and after completing study therapy in order to assess Ki67%. Further treatment including surgery, (neo)adjuvant chemotherapy, radiotherapy, and (neo)adjuvant endocrine therapy will be administered at the discretion of the investigator and according to standard of care outside the clinical trial.

Detailed description: The evaluation of CCCA in the HR+/HER2- invasive lobular breast cancer patient population allows assessment of treatment efficacy with an achievable sample size of HR+/HER2- breast cancer patients within an acceptable and scientifically meaningful duration of recruitment. CCCA can be assessed immediately after last patients end of treatment. Central blinded pathological assessment of CCCA is planned in this study as a standardized preparation of the sampled tissue by the central pathologist. This pathologist is blinded regarding the study therapy administered, i. e. with or without capivasertib.

The addition of capivasertib to fulvestrant in many clinical trials correlates with an improvement in PFS compared to fulvestrant alone in patients with HR+/HER2- locally advanced or metastatic breast cancer. This effect was observed regardless of a PI3K/AKT/mTOR pathway activation. None of the ongoing studies investigate the effects of the combined treatment in invasive lobular breast cancer. Given that these tumors are less likely to respond to chemotherapy, identification of patients that can be spared from chemotherapy is desirable. On the other hand, it is important to identify patients with invasive lobular breast cancer not responding to neoadjuvant ET who might be at increased risk for recurrence, who would therefore potentially benefit from further adjuvant therapies including chemotherapy.

Given the high rates of PI3K pathway alterations in such tumors, it is expected that the CCCA rate could be increased by adding capivasertib to fulvestrant. GBG expect that the potential benefit of improved CCCA rate with a combination treatment compared to fulvestrant monotherapy would outweigh the potential risks due to added toxicity, which has already been shown in clinical trials to be well tolerated by patients.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and followup, and documented according to the local regulatory requirements.
2. Postmenopausal women with age at diagnosis ≥ 18 years.

   Postmenopausal status is defined as:
   * Age ≥60 years
   * Age \<60 years and amenorrhea for at least 12 continuous months with no identified cause other than menopause
   * Bilateral oophorectomy Negative pregnancy test (urine or serum) within 14 days prior to randomization for all postmenopausal women 50 years of age or younger without bilateral oophorectomy
3. Unilateral or bilateral primary untreated lobular invasive carcinoma of the breast. In case of bilateral breast cancer, both sides must be lobular; the lead tumor has to be defined by the investigator based on the inclusion criteria for the respective subtype and the risk status. Lobular histology has to be centrally confirmed.
4. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE) tissue block from core biopsy before the start of neoadjuvant therapy.
5. Centrally confirmed HER2-negative (IHC score 0-1+ or ISH negative according to ASCO/CAP guideline) and HR-positive (≥10% positive stained cells) disease, assessed on the core of diagnostic biopsy. Ki67% \>10% is required. In case of bilateral breast cancer, HER2-negative, HR-positive and lobular histology status has to be confirmed for both sides.
6. Patients with invasive lobular breast cancer at high risk for recurrence defined as cT1c and clinical nodal involvement (cN+) or ≥ cT2 disease (irrespective of nodal involvement).
7. No clinical evidence of distant metastases.
8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
9. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer.
10. The patient must be accessible for scheduled visits, treatment, and followup.
11. Normal cardiac function must be confirmed according to local guidelines.
12. Laboratory requirements:

    Hematology
    * Absolute neutrophil count (ANC) ≥1.5 x 109 / L
    * Platelets ≥100 x 109 / L
    * Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function
    * Total bilirubin \<1.25x ULN
    * AST and ALT \<=1.5x ULN
    * Alkaline phosphatase \<=2.5x ULN Glucose Metabolism
    * HbA1c \<8.0% (63.9 mmol/mol) Renal Function
    * Creatinine \<1.25x ULN or creatinine clearance ≥50 ml/min (if creatinine is above ULN according to Cockroft-Gault)
13. Complete staging work-up prior to the initiation of neoadjuvant therapy as per standard recommendations.

Exclusion Criteria:

1. Female patients of childbearing potential.
2. Excisional biopsy or lumpectomy performed prior to study entry.
3. Surgical axillary staging procedure including sentinel lymph node biopsy prior to randomization. Exceptions: FNA or core biopsy of an axillary lymph node.
4. Any previous treatment including endocrine therapy, chemotherapy, radiotherapy or targeted therapy (including AKT inhibitor or PIK3 inhibitor) for the currently diagnosed breast cancer.
5. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.
6. Known hypersensitivity reaction to one of the compounds or substances used in this protocol.
7. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort).
8. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib.
9. Any contraindication for fulvestrant.
10. Patients with definitive clinical or radiologic evidence of stage IV cancer (metastatic disease) are not eligible.
11. Patients with a history of any malignancy are ineligible with the following exceptions:

    * Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy except for breast cancer.
    * CIS of the cervix, basal cell and squamous cell carcinomas of the skin.
12. History of type I or type II diabetes mellitus requiring insulin.
13. Severe and relevant co-morbidity that would interact with the application of study drugs or the participation in the study, including cerebrovascular incident including transient ischemic attack, or symptomatic pulmonary embolism, active infection requiring intravenous anti-microbial treatment (antibiotics, anti-fungal, and anti-viral drugs) within 1 week of enrolment. Patients with confirmed Gilbert's syndrome may be included in the study.
14. Known medically history of HIV infection, tuberculosis, or hepatitis B.
15. History of and/or active cardiac disease that would preclude the use of study treatments. This includes but is not confined to any of the following cardiac criteria:

    * Clinically significant cardiac dysfunction including heart failure (NYHA II-IV), active ventricular arrhythmias requiring medication or arrhythmias requiring a pacemaker, and history of a myocardial infarction within 6 months prior to randomization, angina pectoris, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, angioplasty, or vascular stent.
    * Mean resting QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from 3 consecutive ECGs.
    * Increased risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled electrolyte disorders (e.g., hypocalcemia, hypokalemia, or hypomagnesemia), potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval.
16. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving therapy.
17. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent.
18. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension or hypotension (BP \<50mmHg), significant aneurysm, renal transplant and active bleeding diseases).
19. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
20. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

Primary outcomes:
measure: To assess complete cell cycle arrest (CCCA).
timeFrame: Up to 14 weeks
Secondary outcomes:
measure: To asses safety and tolerability
timeFrame: Up to 14 weeks
measure: To assess patholgogical complete response rate (pCR) by different definitions
timeFrame: Up to 14 weeks
measure: To assess breast conservation rate (BCS)
timeFrame: Up to 14 weeks
measure: To assess invasive disease-free survival (iDFS) and overall survival (OS)
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Augsburg
country: Germany
facility: Haematologie-Onkologie im Zentrum MVZ GmbH
city: Berlin
country: Germany
facility: Charité
city: Bielefeld
country: Germany
facility: Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR
city: Bremen
country: Germany
facility: Hämato-Onkologie im Medicum - Onkologie und Hämatologie
city: Cottbus
country: Germany
facility: Carl-Thiem-Klinikum gGmbH - Frauenklinik
city: Dortmund
country: Germany
facility: Kath. St. Paulus GmbH - Klinische Forschung
city: Essen
country: Germany
facility: Universitätsklinikum Essen - Klinik für Frauenheilkunde und Geburtshilfe
city: Frankfurt am Main
country: Germany
facility: Klinikum Frankfurt Höchst GmbH - Klinik für Gynäkologie und Geburtshilfe
city: Freiburg im Breisgau
country: Germany
facility: Praxis für Interdisziplinäre Onkologie & Hämatologie
city: Hamburg
country: Germany
facility: Mammazentrum Hamburg - am Krankenhaus Jerusalem
city: Homburg
country: Germany
facility: Universitätsklinikum des Saarlandes - Frauenklinik
city: Kassel
country: Germany
facility: Klinikum Kassel GmbH - Frauenklinik
city: Köln
country: Germany
facility: Kliniken der Stadt Köln GmbH - Brustzentrum Köln-Holweide
city: Leipzig
country: Germany
facility: St. Elisabethen-Krankenhaus gGmbH - Senologie / Brustzentrum
city: Münster
country: Germany
facility: Medizinisches Versorgungszentrum MediaVita GmbH Muenster
city: Oldenburg
country: Germany
facility: Klinikum Oldenburg AöR - Universitätsklinik für Innere Medizin - Onkologie
city: Ravensburg
country: Germany
facility: MVZ für Hämatolgie und Onkologie Ravensburg GmbH - Studienzentrum
city: Rostock
country: Germany
facility: Klinikum Südstadt - Universitätsfrauenklinik
city: Schweinfurt
country: Germany
facility: Leopoldina-Krankenhaus der Stadt Schweinfurt - Frauenklinik
city: Stendal
country: Germany
facility: Johanniter-Krankenhaus Genthin-Stendal - Klinik für Frauenheilkunde und Geburtshilfe
city: Torgau
country: Germany
facility: Kreiskrankenhaus Torgau - Gynäkologie
city: Troisdorf
country: Germany
facility: Praxisnetzwerk Haematologie und internistische Onkologie Ueberoertliche Berufsausuebungsgemeinschaft - Hämatologie und Onkologie
city: Witten
country: Germany
facility: Marienhospital Witten - Brustzentrum
city: Worms
country: Germany
facility: Klinikum Worms gGmbH - Frauenklinik
city: Wuppertal
country: Germany
facility: Helios Klinikum Wuppertal GmbH - Landesfrauenklinik
Study officials:
affiliation: ESMO, ASCO, AGO Kommission Mamma (member); Goethe University Frankfurt; GBG Forschungs GmbH
name: Sibylle Loibl, Prof. Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5.